Controlled Study for Prolonged Chemotherapy, Immunotherapy, and Chemotherapy Plus Immunotherapy as an Adjuvant to Surgery in Malignant Melanoma (Trial 6): Preliminary Report

Author(s):  
U. Veronesi ◽  
G. Beretta
1985 ◽  
Vol 6 (4) ◽  
pp. 411-413
Author(s):  
F. Marchionni ◽  
S. Ricci ◽  
R. Luccioli ◽  
C. Piccolini ◽  
E. Signorini

1973 ◽  
Vol 59 (3) ◽  
pp. 239-248 ◽  
Author(s):  
Gianni Beretta ◽  
Emilio Bajetta ◽  
Gianni Bonadonna ◽  
Gabriele Tancini ◽  
Sergio Orefice ◽  
...  

The toxic and therapeutic effects obtained with a triple drug combination (BCNU, DTIC and VCR) administered in a cyclic fashion to 41 unselected evaluable patients with metastatic malignant melanoma are reported. Side effects were moderate and reversible. The overall regression rate was 44% without difference between males and females. Partial remission (> 50%) plus complete remission was 19.5% with an average duration of 5.1 months (1–20+). With the exclusion of bone lesions, all types of metastases showed regression especially those located in the soft tissues (lymph nodes and skin). The actuarial analysis of survival shows that responders live twice as long as non responders (median survival 12 months versus 6 months). However, the superior therapeutic efficacy of BCNU + DTIC + VCR over DTIC alone in metastatic melanoma remains to be demonstrated. A controlled study with different triple combinations is now in progress.


2000 ◽  
Vol 13 (4) ◽  
pp. 589-609 ◽  
Author(s):  
Barry Krakow ◽  
Michael Hollifield ◽  
Ron Schrader ◽  
Mary Koss ◽  
Dan Tandberg ◽  
...  

1976 ◽  
Vol 274 (1) ◽  
pp. 596-607 ◽  
Author(s):  
Frank M. Howard ◽  
Drake D. Duane ◽  
Edward H. Lambert ◽  
Jasper R. Daube

Sign in / Sign up

Export Citation Format

Share Document